Al Mofadaly Trading Co.

11/06/2023

https://www.youtube.com/watch?v=JoMtChBrv2Y

Riyadh First Health Cluster Riyadh Cluster 1KSME-ECMOChairpersons Dr. Mohamed Azzam Critical Care Consultant Dr. Ahmed Rabie Critical Care ConsultantECMO for...

13/04/2021

11/04/2018

In a recent press release, Healthmark Industries announced the addition of the SonoCheckTM Hook to its ProFormanceTM Cleaning Verification product line.

05/04/2018

Speaker & Trainer Dr. Yasir Madani & Mr. Abdul Hadi Al-Jali has successfully completed the end user training
For
Medos | Xenios AG - Lung and heart therapies in Al-Jalila Hospital - Dubai

Medos offers a comprehensive product portfolio for cardiac surgery. Our goal is to develop innovative therapeutic solutions and to provide them to our customers.

 XENIOS is the first to offer a complete product family of state-of-the-art solutions for minimally invasive treatment of acute and chronic lung failure.
 XENIOS therapy brand medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients.
 XENIOS is the first to offer synchronized cardiac assist, which provides cardiac support in harmony with each heartbeat, designed to unite myocardial protection with organ perfusion.

Therapy

Coronary artery bypass surgery
Despite all the advancements in interventional catheter therapy, cardiac surgical therapy of coronary heart disease (CHD) still offers proven qualitative advantages, especially in stable CHD, which is clearly reflected in the current joint guidelines from the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

Valve surgery

The options of conventional valve surgery now extend from valve replacement with established mechanical solutions as well as the significantly increasing use of biological valve prosthetics, through to complex reconstructive surgical techniques. Especially the conservative procedures on the mitral and aorta valves can have a very positive effect on the life quality of these patients operated. These complex techniques are often time-consuming and therefore benefit not least from advancements in modern perfusion technology.

Congenital heart defects

Modern perfusion technology allows specialised cardiac surgeons to correct even complex congenital heart defects in procedures that are usually just as complex or at least allows them to offer palliative solutions with multi-stage approaches, as necessary. Consequently, the number of adults with corrected congenital heart defects requiring specialised medical support, usually lifelong, is on the increase.

Thoracic vascular surgery

Thoracic vascular surgery encompasses both elective surgical treatment of aortic aneurysms and treatment of aortic dissections, whereby, in the majority of cases, the latter usually represents an acute, life-threatening situation. Therapy usually involves prosthetic replacement of the vascular region affected, whereby endovascular procedures are increasingly deployed on their own or in combination with conventional surgical procedures.

Heart transplantation

Today the transplantation of a donor heart is still a severe surgical intervention which is also accompanied by emotional and ethical aspects to a considerable extent. However, the biggest challenge is still the insufficient number of donor organs available – a situation conducive to the increased use of ventricular assist systems in the future.

05/04/2018

Method of transferring patient on Medos Ecmo
A demo transfer of medos Ecmo with battery drive pump

Medos offers a comprehensive product portfolio for cardiac surgery. Our goal is to develop innovative therapeutic solutions and to provide them to our customers.

 XENIOS is the first to offer a complete product family of state-of-the-art solutions for minimally invasive treatment of acute and chronic lung failure.
 XENIOS therapy brand medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients.
 XENIOS is the first to offer synchronized cardiac assist, which provides cardiac support in harmony with each heartbeat, designed to unite myocardial protection with organ perfusion.

Therapy

Coronary artery bypass surgery
Despite all the advancements in interventional catheter therapy, cardiac surgical therapy of coronary heart disease (CHD) still offers proven qualitative advantages, especially in stable CHD, which is clearly reflected in the current joint guidelines from the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

Valve surgery

The options of conventional valve surgery now extend from valve replacement with established mechanical solutions as well as the significantly increasing use of biological valve prosthetics, through to complex reconstructive surgical techniques. Especially the conservative procedures on the mitral and aorta valves can have a very positive effect on the life quality of these patients operated. These complex techniques are often time-consuming and therefore benefit not least from advancements in modern perfusion technology.

Congenital heart defects

Modern perfusion technology allows specialised cardiac surgeons to correct even complex congenital heart defects in procedures that are usually just as complex or at least allows them to offer palliative solutions with multi-stage approaches, as necessary. Consequently, the number of adults with corrected congenital heart defects requiring specialised medical support, usually lifelong, is on the increase.

Thoracic vascular surgery

Thoracic vascular surgery encompasses both elective surgical treatment of aortic aneurysms and treatment of aortic dissections, whereby, in the majority of cases, the latter usually represents an acute, life-threatening situation. Therapy usually involves prosthetic replacement of the vascular region affected, whereby endovascular procedures are increasingly deployed on their own or in combination with conventional surgical procedures.

Heart transplantation

Today the transplantation of a donor heart is still a severe surgical intervention which is also accompanied by emotional and ethical aspects to a considerable extent. However, the biggest challenge is still the insufficient number of donor organs available – a situation conducive to the increased use of ventricular assist systems in the future.

05/04/2018

Speaker & Trainer Mr. Abdul Hadi Al-Jali Dr. Yasir Madani has successfully completed the end user training
for Novalung | Xenios AG - Solutions for Lung Failure
in
Al Jalila Children’s Specialty Hospital. – Dubai

Solutions for Lung Failure

The aim of novalung is to create new solutions for the treatment of acute and chronic lung failure. Today Novalung is the first to offer a complete product portfolio for extrapulmonary lung assist.

novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, novalung products’ smaller cannulas lower the threshold for adoption. In short, novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD

05/04/2018

Ready for Presentation and workshop at Al-Jalila Hospital in Dubai

02/04/2018

Speaker & Trainer Mr. Abdul Hadi Al-Jali Dr. Yasir Madani & Eng Mohammed Baroudy has successfully completed the end user training for Novalung | Xenios AG - Solutions for Lung Failure
in
Prince Sultan Military Medical City – Riyadh

Solutions for Lung Failure
The aim of novalung is to create new solutions for the treatment of acute and chronic lung failure. Today Novalung is the first to offer a complete product portfolio for extrapulmonary lung assist.

novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, novalung products’ smaller cannulas lower the threshold for adoption. In short, novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD

02/04/2018

Speaker & Trainer Mr. Abdul Hadi Al-Jali Dr. Yasir Madani & Eng Mohammed Baroudy has successfully completed the end user training for Novalung | Xenios AG - Solutions for Lung Failure
in
Prince Sultan Military Medical City – Riyadh

Solutions for Lung Failure
The aim of novalung is to create new solutions for the treatment of acute and chronic lung failure. Today Novalung is the first to offer a complete product portfolio for extrapulmonary lung assist.

novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, novalung products’ smaller cannulas lower the threshold for adoption. In short, novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD

29/03/2018

Speaker & Trainer Mr. Saeed Mohd Al-Mofadaly, Dr. Abdul Hadi Al-Jali & Dr. Yasir Madani has successfully completed the end user training for Medos | Xenios AG - Lung and heart therapies in Shaikh Khalifa Medical City – UAE

Medos offers a comprehensive product portfolio for cardiac surgery. Our goal is to develop innovative therapeutic solutions and to provide them to our customers.

 XENIOS is the first to offer a complete product family of state-of-the-art solutions for minimally invasive treatment of acute and chronic lung failure.
 XENIOS therapy brand medos has been making German medical technology history since 1987, for the benefit of cardiac surgeons, perfusionists and patients.
 XENIOS is the first to offer synchronized cardiac assist, which provides cardiac support in harmony with each heartbeat, designed to unite myocardial protection with organ perfusion.

Therapy

Coronary artery bypass surgery
Despite all the advancements in interventional catheter therapy, cardiac surgical therapy of coronary heart disease (CHD) still offers proven qualitative advantages, especially in stable CHD, which is clearly reflected in the current joint guidelines from the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

Valve surgery

The options of conventional valve surgery now extend from valve replacement with established mechanical solutions as well as the significantly increasing use of biological valve prosthetics, through to complex reconstructive surgical techniques. Especially the conservative procedures on the mitral and aorta valves can have a very positive effect on the life quality of these patients operated. These complex techniques are often time-consuming and therefore benefit not least from advancements in modern perfusion technology.

Congenital heart defects

Modern perfusion technology allows specialised cardiac surgeons to correct even complex congenital heart defects in procedures that are usually just as complex or at least allows them to offer palliative solutions with multi-stage approaches, as necessary. Consequently, the number of adults with corrected congenital heart defects requiring specialised medical support, usually lifelong, is on the increase.

Thoracic vascular surgery

Thoracic vascular surgery encompasses both elective surgical treatment of aortic aneurysms and treatment of aortic dissections, whereby, in the majority of cases, the latter usually represents an acute, life-threatening situation. Therapy usually involves prosthetic replacement of the vascular region affected, whereby endovascular procedures are increasingly deployed on their own or in combination with conventional surgical procedures.

Heart transplantation

Today the transplantation of a donor heart is still a severe surgical intervention which is also accompanied by emotional and ethical aspects to a considerable extent. However, the biggest challenge is still the insufficient number of donor organs available – a situation conducive to the increased use of ventricular assist systems in the future.

25/03/2018

Solutions for Lung Failure
The aim of novalung is to create new solutions for the treatment of acute and chronic lung failure. Today Novalung is the first to offer a complete product portfolio for extrapulmonary lung assist.

novalung is the world‘s first lung failure therapy platform, which competes favorably against one-product offerings. The novalung product family enables therapies for lung failure that are adapted to specific indications. In addition, novalung products’ smaller cannulas lower the threshold for adoption. In short, novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The novalung platform performs any level of CO2 removal and oxygenation in acute respiratory failure / AECOPD.